Part 2: Looking back at 50 years of innovation in ophthalmology
To mark Ophthalmology Times’ 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.
Related Articles
The Good, the Bad and the Office-Based Surgery
By Andrew Beers, Associate Editor H ospitals have their advantages and disadvantages. Ambulatory surgery centers do as well. But how about office-based surgery and its…
Regression of Retinal Metastasis with Combined Chemotherapy and Immunotherapy
A 61-year-old woman with recently diagnosed lung adenocarcinoma presented with rapid vision loss in her left eye. Ophthalmoscopy revealed an elevated white-yellow retinal mass (A),…
2025
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
Current Issue Table of Contents: Ophthalmology Glaucoma
Volume 8 Issue 4 p327-426, e9-e14 Your session will expire shortly. If you are still working, click the ‘Keep Me Logged In’ button below. If…
NIH Eye Contest 2025
This video highlights the AI Eye and Smart Cane, innovative assistive devices designed to help visually impaired individuals navigate their surroundings with…
Current Issue Table of Contents: Ophthalmology
Volume 132 Issue 8 p853-960, e1-e152 Your session will expire shortly. If you are still working, click the ‘Keep Me Logged In’ button below. If…
RWC Update: Surgical Intervention in Pediatric Uveitis; L-Shape Technique: Engineering for Intraocular Foreign Bodies; Post-Viral Frosted Branch Angiitis | Ophthalmic Surgery, Lasers and Imaging Retina
Can’t sign in? Forgot your username? Can’t sign in? Forgot your password? The corresponding author is Kourous A. Rezaei at Ophthalmic Surgery, Lasers and Imaging…
Pinhole pupilloplasty vs. pinhole IOL: Which do you prefer for highly aberrated corneas?
In recent years, the issue of correcting higher-order aberrations has become increasingly relevant, particularly in patients who have undergone surgery such as keratotomy or keratoplasty…
Promoting Genuine Podium Inclusivity
Amid conference organizers’ efforts to promote diversity, David Lockington proposes a simple way to make sure more voices are truly heard
Harrow enters into agreement with Samsung Bioepis for commercial rights to its ophthalmology biosimilar portfolio
Included in the agreement are ranibizumab-nuna 0.05 mL injection (BYOOVIZ), referencing LUCENTIS (ranibizumab), and aflibercept-yszy 0.05 mL injection (OPUVIZ), referencing EYLEA (aflibercept).